Boehringer Ingelheim GmbH has expanded its oncology portfolio to include oncolytic virus technology through a collaboration with privately held ViraTherapeutics GmbH of Austria. The deal is potentially worth €210 million. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
